{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:04:56Z","timestamp":1791230696221,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the significant survival benefit offered by immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC), a subset of patients still develop drug resistance. Recent evidence suggests that proton pump inhibitors (PPIs) may influence the therapeutic efficacy of ICIs, but the clinical relevance of this interaction remains unclear. This meta-analysis aims to systematically evaluate the association between concomitant PPIs use and clinical outcomes in HCC patients receiving ICIs therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of the PubMed, Embase (via Ovid), and Web of Science databases was conducted to identify relevant studies published before May 14, 2025. The primary endpoints of the meta-analysis were overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five retrospective studies comprising a total of 1,257 patients were included, of whom 606 (48.2%) received PPIs concurrently with ICIs. The meta-analysis showed no statistically significant association between PPIs use and either OS (HR: 1.04, 95% CI: 0.88-1.24, P = 0.64) or PFS (HR: 0.92, 95% CI: 0.74-1.14, P = 0.44). These findings were further supported by a Bayesian sensitivity analysis performed to address the uncertainty inherent in a limited number of studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on the current evidence from retrospective studies, concomitant use of PPIs does not appear to significantly affect survival outcomes in HCC patients treated with ICIs. However, given the inherent limitations of the included studies, this conclusion should be interpreted with caution and warrants validation through prospective investigations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251026028<\/jats:ext-link>\n                      , CRD420251026028.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1717420","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:51:49Z","timestamp":1771483909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The influence of concomitant proton pump inhibitors use on treatment efficacy in hepatocellular carcinoma patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yangfei","family":"Duan","sequence":"first","affiliation":[{"name":"School of Public Health, Zhengzhou University","place":["Zhengzhou, Henan, China"]},{"name":"Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qitai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Feng","sequence":"additional","affiliation":[{"name":"Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jing","sequence":"additional","affiliation":[{"name":"Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[{"name":"Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health, Zhengzhou University","place":["Zhengzhou, Henan, China"]},{"name":"Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]},{"name":"School of Life Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]},{"name":"State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University","place":["Zhengzhou, Henan, China"]},{"name":"Zhongyuan Cell Therapy and Immunotherapy Laboratory, Henan Academy of Innovations in Medical Science","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02295-2","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach","volume":"15","author":"de La Rochefoucauld","year":"2020","journal-title":"Intern Emerg Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1972969","article-title":"PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin On Investigat Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02282-w","article-title":"Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer","volume":"22","author":"Iglesias-Santamar\u00eda","year":"2020","journal-title":"Clin Trans Oncol Off Publ Fed Spanish Oncol Societies Natl Cancer Institute Mexico"},{"key":"B9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.drup.2015.08.004","article-title":"Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach","volume":"23","author":"Taylor","year":"2015","journal-title":"Drug Resist Updat"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-320204","article-title":"Interaction between drugs and the gut microbiome","volume":"69","author":"Weersma","year":"2020","journal-title":"Gut"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s10787-024-01467-2","article-title":"Efficacy and safety of proton pump inhibitors on cardiovascular events and inflammatory factors in patients with upper gastrointestinal bleeding undergoing dual antiplatelet therapy","volume":"32","author":"Yang","year":"2024","journal-title":"Inflammopharmacology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103752","article-title":"Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis","volume":"78","author":"Dar","year":"2022","journal-title":"Ann Med Surg (2012)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1018411","article-title":"Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S912","DOI":"10.1016\/S0168-8278(20)32252-2","article-title":"Effect of antibiotics, proton pump inhibitors and steroids on survival and response to immune-checkpoint inhibitors in patients with hepatocellular carcinoma","volume":"73","author":"Lee","year":"2020","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-024-01095-7","article-title":"Concomitant medications alter clinical outcomes in patients with advanced digestive tract cancer receiving PD-1 checkpoint inhibitors combined with antiangiogenetic agents","volume":"55","author":"Wang","year":"2024","journal-title":"J Gastrointest Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13905","article-title":"Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis","volume":"53","author":"Hatanaka","year":"2023","journal-title":"Hepatol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.210","article-title":"The impact of statins and proton-pump inhibitors on immune checkpoint inhibition in patients with hepatocellular carcinoma","volume":"35","author":"Hobeika","year":"2024","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211010937","article-title":"Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma","volume":"13","author":"Jun","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.14139","article-title":"Impact of antibiotics and chronic medications on efficacy of immune checkpoint inhibitors in patients with hepatocellular carcinoma","volume":"21","author":"Ng","year":"2025","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.S464033","article-title":"The impact of proton pump inhibitors on the efficacy of immune checkpoint inhibitor combinations in patients with HBV-associated advanced hepatocellular carcinoma","volume":"11","author":"Wang","year":"2024","journal-title":"J Hepatocellular Carcinoma"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14070685","article-title":"Natural health products for anti-cancer treatment: evidence and controversy","volume":"14","author":"Conti","year":"2024","journal-title":"J Pers Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00890-z","article-title":"The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors","volume":"23","author":"Stone","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211012038","article-title":"The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy","volume":"28","author":"Guven","year":"2022","journal-title":"J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(25)00059-7","article-title":"Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial","volume":"10","author":"Shi","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221111703","article-title":"Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Chen","year":"2022","journal-title":"Ther Adv In Med Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-57","article-title":"Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis","volume":"10","author":"Biswas","year":"2012","journal-title":"BMC Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Sci (New York NY)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581098","article-title":"Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances","volume":"16","author":"Xie","year":"2025","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2022.2847","article-title":"Avoiding definitive conclusions in meta-analysis of heterogeneous studies with small sample sizes","volume":"148","author":"Zhou","year":"2022","journal-title":"JAMA Otolaryngol\u2013 Head Neck Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12856","article-title":"Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re-analysis of a meta-analysis","volume":"7","author":"Zhou","year":"2023","journal-title":"JGH open: an Open Access J Gastroenterol Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1717420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:51:50Z","timestamp":1771483910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1717420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1717420"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1717420","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1717420"}}